MedTrace Logo

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

NCT05751850 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 778

Last updated 2024-05-09

No results posted yet for this study

Summary

The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.

Conditions

  • First-line Treatment of Advanced Pancreatic Cancer

Interventions

DRUG

HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate

HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate

DRUG

nab-paclitaxel; gemcitabine

nab-paclitaxel in combination with gemcitabine

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-13
Primary Completion
2024-12-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05751850 on ClinicalTrials.gov